LUNG CANCER DIAGNOSTIC AND SCREENING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Lung Cancer Diagnostic and Screening Market Size and Share Analysis - 2026 To 2033

Lung Cancer Diagnostic and Screening Market is estimated to be valued at USD 3,287.8 Mn in 2026 and is expected to reach USD 6,530.4 Mn in 2033, exhibiting a compound annual growth rate (CAGR) of 10.3% from 2026 to 2033. The lung cancer diagnostic and screening market is witnessing strong transformation driven by early detection mandates and advanced imaging technologies such as low-dose CT (LDCT), which the USPSTF reaffirmed in March 2021 for adults aged 50–80 years with a ≥20 pack-year smoking history and reported ~20% mortality reduction in high-risk populations through screening programs. CDC guidelines (October 2024) further confirm eligibility expansion to current or former smokers within 15 years. According to WHO cancer updates (February 2024), lung cancer remains the leading cause of cancer death globally, reinforcing demand for screening. In 2026, AI-based nodule detection systems and liquid biopsy innovations are accelerating precision diagnostics, improving early-stage detection rates and clinical decision-making efficiency across healthcare systems worldwide.

(Source: USPSTF Lung Cancer Screening Recommendation; CDC; WHO)

Key Takeaways

• Imaging test is expected to account the largest share of 45.2% in 2026. The imaging test, particularly low-dose computed tomography (LDCT), remains the dominant test type in the lung cancer diagnostic and screening market due to its superior early-stage detection capability, high sensitivity, and strong clinical validation in high-risk populations. According to the CDC (May 2026), LDCT is the only recommended screening method, as chest X-rays and biomarker tests are not effective for early detection. USPSTF guidelines show LDCT can reduce lung cancer mortality by about 20% in high-risk groups. WHO reports also highlight lung cancer as the leading cause of cancer death, reinforcing demand for accurate imaging. In 2026 research, AI-enhanced CT screening improves nodule detection and supports faster, earlier diagnosis, strengthening its dominance in clinical practice.
• Non-small cell lung cancer (NSCLC) will dominate with 80.0% in 2026. In the Lung Cancer Diagnostic and Screening Market, Non-small cell lung cancer (NSCLC) is the dominant segment by cancer type. This is because NSCLC accounts for the majority of lung cancer cases globally, with the American Cancer Society stating that around 80%–85% of lung cancers are NSCLC. In contrast, small cell lung cancer represents a much smaller share; CDC data shows that small cell carcinoma accounted for around 12% of U.S. lung cancer cases in 2022. NSCLC also drives higher demand for diagnostic imaging, biopsy, molecular testing, biomarker profiling, and screening follow-up because it includes major subtypes such as adenocarcinoma and squamous cell carcinoma.
• Hospital associated labs hold the dominant share of 46.8% in 2026. Hospital associated laboratories dominate the lung cancer diagnostic and screening market due to their strong integration with oncology and radiology departments, enabling faster diagnostic decision-making. According to the CDC (published March 2026), lung cancer causes about ~236,000 new cases annually in the U.S., with most diagnoses initiated in hospital settings through CT and biopsy workflows. The WHO Global Cancer Observatory (February 2026) highlights that lung cancer remains the leading cause of cancer deaths worldwide, increasing hospital-based screening demand. A key factor is imaging dominance CT and PET-CT account for the majority of first-line detection, as supported by the American Cancer Society (January 2026). Hospitals consolidate imaging, pathology, and molecular testing in one setting, making them the primary diagnostic hub over independent labs.
• North America is expected to acquire the dominant share of 33.5% in 2026, attributed to strong investment in R&D funding, advanced infrastructure and ecosystem. North America remains dominant in the lung cancer diagnostic and screening market because the region combines high disease burden, reimbursed LDCT screening, and rapid imaging-technology adoption. In June 2026, CDC reported 228,058 new U.S. lung cancers in 2023 and 128,663 deaths in 2024, while ACS, published January 2026, estimated 229,410 new U.S. lung and bronchus cases and 124,990 deaths in 2026. Medicare covers annual LDCT for eligible adults aged 50–77 with at least 20 pack-years, supporting access. Imaging leads because CDC states LDCT is the only recommended screening test; in June 2026, NIH-funded smartphone/liquid-biopsy research complemented, not replaced, CT-based pathways.

(Source: CDC; Cancer.org; Medicare.gov; CDC; UCONN.Edu)

Segmental Insights 

Why is Imaging Test Acquiring the Largest Market Share

Imaging Test is projected to account for the largest share in 2026, representing approximately 45.2% of the total volume. Imaging tests dominate the lung cancer diagnostic and screening market due to their role as the first-line detection method for early-stage tumors and lung nodules. Low-dose CT and PET-CT offer high sensitivity, enabling early identification before symptoms appear. Strong government-backed screening programs and clinical guidelines from CDC and WHO further reinforce imaging as the primary diagnostic pathway in hospitals. For instance, CDC (Updated May 2026) states that the recommended lung cancer screening test is low-dose CT (LDCT) for high-risk individuals, confirming CT as the standard first-line screening modality in the U.S. The U.S. Preventive Services Task Force (USPSTF, reaffirmed guideline 2025–2026 updates) recommends annual LDCT screening for adults aged 50–80 with ≥20 pack-year smoking history, covering the entire high-risk population eligible for screening. The USPSTF evidence base shows LDCT screening provides a ~20% reduction in lung cancer mortality compared with chest X-ray screening (National Lung Screening Trial evidence used in guidelines).

Non-Small Cell Lung Cancer (NSCLC) holds the Largest Market Share

Based on cancer type, Non-Small Cell Lung Cancer (NSCLC) dominate the market, accounting for a significant 80.0% share in 2026. The non-small cell lung cancer (NSCLC) segment is dominant because it represents the largest case pool, creating higher need for screening, biopsy confirmation, molecular profiling, and follow-up imaging. The American Cancer Society notes that NSCLC accounts for about 80%–85% of lung cancers, while its January 2026 statistics estimated 229,410 new U.S. lung and bronchus cancer cases and 124,990 deaths in 2026. This large burden keeps hospitals focused on NSCLC detection pathways, especially adenocarcinoma and squamous cell carcinoma. Imaging remains dominant because CDC, published May 2026, states low-dose CT is the recommended lung cancer screening test for early detection in practice.

(Source: American Cancer Society; CDC lung cancer screening guidance, published May 2026; cancer.org)

Which Hospital Associated Labs segment dominates the market? 

Hospital associated labs dominate the global lung cancer diagnostic and screening market with the share of 46.8% because hospitals integrate radiology, pathology, oncology, biopsy, and molecular testing under one clinical workflow. The American Cancer Society, published in January 2026, estimated 229,410 new lung and bronchus cancer cases and 124,990 deaths in the U.S., supporting high hospital diagnostic volume. CDC, published in May 2026, stated that low-dose CT is the recommended screening test for high-risk adults aged 50–80 with 20 pack-year history, and only about 18% of eligible adults were screened. This makes imaging dominant, as hospital-based LDCT, CT, and PET-CT trigger follow-up biopsy and laboratory confirmation.

Global Lung Cancer Diagnostic and Screening Market– Drivers

Increasing Research & Development activities for early detection of cancer

Increasing Research & Development activities for early detection of cancer are expected to propel the growth of the global lung cancer diagnostic and screening market over the forecast period. For instance, in April 2020, researchers at the Massachusetts Institute of Technology (MIT) developed a nanoparticle-based approach that allows the early diagnosis of lung cancer through a simple urine test. The strategy detects biomarkers resulting from the interaction of peptide-coated nanoparticles with disease-associated proteases in the tumor microenvironment. Experiments in two different mouse models of lung cancer showed that the urine test could detect tumors as small as 2.8 mm. The researchers hope that this type of noninvasive diagnosis could reduce the number of false positives associated with an existing test method and help to detect more tumors in the early stages of the disease.

AI-based nodule detection and risk stratification and Expansion of LDCT screening programs are transforming the Global Lung Cancer Diagnostic and Screening Market

Expansion of LDCT screening programs and AI-based nodule detection & risk stratification are the major factors creating the opportunity for the growth of the global lung cancer diagnostic and screening market over the forecast period. Low-dose CT remains the recommended screening test for lung cancer, creating strong demand for imaging centers, CT systems, radiology services, and screening workflow solutions. CDC updated its lung cancer screening page in May 2026, confirming LDCT as the recommended screening method. Furthermore, AI tools can help radiologists prioritize suspicious lung nodules, reduce missed findings, and improve diagnostic decision-making. For instance, in April 2026, Coreline Soft reported that Germany’s national low-dose CT lung cancer screening program requires mandatory AI-assisted detection software to ensure standardized, high-quality diagnosis workflows. The guideline mandates CE-marked, MDR-compliant CAD systems with PACS/RIS integration, supporting dual-reading interpretation and structured reporting across screening centers. Framework emphasizes GDPR compliance, interoperability, and consistent nodule detection performance, positioning AI as a core infrastructure component in nationwide lung cancer screening implementation in system.

Current Events and Their Impact on the Global Lung Cancer Diagnostic and Screening Market

Global Lung Cancer Diagnostic and Screening Market: Key Trends

• Increasing awareness campaigns to increase the number of diagnostic and screening test

Increasing awareness campaigns to increase the number of diagnostic and screening tests for lung cancer are expected to drive the growth of the global lung cancer diagnostic and screening market over the forecast period. For instance, in November 2022, the government of Canada initiated Lung Cancer Awareness Month to raise awareness about lung cancer and the actions to help prevent it and reduce the stigma associated with this disease.

• Expansion of Low-Dose CT (LDCT)–Based National Screening Programs

Government-led LDCT screening programs are expanding globally, making imaging the backbone of early lung cancer detection. These programs focus on high-risk populations (smokers aged 50–80) to identify lung nodules before symptoms appear. For example, the CDC (May 2026) confirms LDCT as the only recommended screening test in the U.S., while Australia’s national program (2025 rollout continuing into 2026) covers high-risk individuals using mobile CT units, significantly increasing screening penetration.

• Rise of AI-Assisted Imaging for Early Detection

AI-based radiology tools are increasingly integrated into CT and PET-CT workflows to improve accuracy in detecting small lung nodules and reduce diagnostic delays. In 2026, European Cancer Imaging Initiative projects expanding AI training datasets to over 60 million imaging records, enabling better algorithm validation. Hospitals are adopting AI triage systems that prioritize high-risk scans, improving early detection efficiency and reducing radiologist workload in lung cancer screening programs.

• Growth of Liquid Biopsy and Companion Diagnostics

Liquid biopsy is gaining momentum as a non-invasive complement to imaging, especially for NSCLC molecular profiling. The U.S. FDA (February 2026) approved targeted therapies such as HER2-directed treatments requiring FDA-authorized diagnostic testing, increasing demand for biomarker assays. This trend is expanding the role of hospital laboratories, where ctDNA, NGS panels, and blood-based tests are increasingly used alongside imaging for precision oncology decision-making.

• Expansion of Hospital-Based Integrated Diagnostic Pathways

Hospitals are becoming centralized hubs combining imaging, pathology, and molecular testing under one workflow. CDC data (May 2026) indicates only ~18% screening uptake in eligible U.S. populations, pushing hospitals to expand diagnostic capacity. Integrated cancer centers ensure that LDCT screening immediately flows into biopsy and molecular testing, improving diagnostic speed and increasing hospital associated lab dominance in the global market.

• Increasing Government Funding and Cancer Screening Initiatives

Governments and global health bodies are increasing funding for lung cancer early detection programs. The WHO (2026 updates) continues to emphasize lung cancer as the leading cause of cancer mortality globally, driving policy action toward screening expansion. EU4Health and national programs in the UK and EU are investing in population-based screening pilots, boosting demand for CT infrastructure, diagnostic labs, and oncology imaging services across hospitals.

Regional Insights

Global Lung Cancer Diagnostic and Screening Market- Regional Analysis

North America is estimated to hold 33.5% of the market share in 2026. The global lung cancer diagnostic and screening market is expected to witness significant growth in the coming years, driven by the high prevalence of lung cancer. The increasing prevalence of neurological disorders is contributing to the growth of the lung cancer diagnostic and screening market in the North America region. For instance, according to data published by the American Society of Clinical Oncology (ASCO) on March 3, 2023, worldwide, lung cancer is the second most commonly diagnosed cancer, while NSCLC (non-small cell lung cancer) is the most common type of lung cancer in the U.S., accounting for 81% of all lung cancer diagnoses.

Asia Pacific Lung Cancer Diagnostic and Screening Market Trends

Asia-Pacific is the fastest-growing region in the lung cancer diagnostic and screening market because the region carries a large undiagnosed patient pool, high smoking and air-pollution exposure, aging populations, and expanding national screening capacity. WHO, updated April 2026, reported lung cancer as the leading cancer, with 2.5 million cases and 1.8 million deaths globally, and linked most preventable cases to tobacco, air pollution, and occupational exposure. In February 2026, India’s PIB said early detection is a major lung cancer challenge and released national evidence-based guidelines to strengthen diagnosis pathways. In April 2026, ASCO Post reported China’s LUNG-CARE study of nearly 12,000 adults, where LDCT screening raised stage-I detection to 81.5% versus 25.1%, supporting wider CT screening adoption.

High Disease Burden and Structured Screening Guidelines is Accelerating the Lung Cancer Diagnostic and Screening Market Demand in United States

The U.S. dominates the North America lung cancer diagnostic and screening market due to its high disease burden, structured screening guidelines, advanced hospital imaging capacity, and rapid adoption of precision diagnostics. The American Cancer Society, published in January 2026, estimated 229,410 new lung cancer cases and 124,990 deaths in the U.S., creating strong diagnostic demand. CDC, updated in May 2026, states that low-dose CT is the recommended screening test for high-risk adults and that only about 18% of eligible U.S. adults were screened, leaving major room for screening expansion. This supports imaging dominance, as LDCT is the first-line detection tool. In February 2026, the U.S. FDA approved zongertinib for HER2-mutated NSCLC detected by an FDA-authorized test, boosting biomarker testing adoption.

Who are the Major Companies in Lung Cancer Diagnostic and Screening Market

Some of the major key players in Lung Cancer Diagnostic and Screening Market are Abbott, Amgen Inc., Illumina, Inc., Thermo Fisher Scientific Inc., Lepu Medical Technology (Beijing)Co.,Ltd., AstraZeneca, F. Hoffmann-La Roche Ltd, Laboratory Corporation of America Holdings., Agilent Technologies, Inc., QIAGEN, Quest Diagnostics Incorporated., NeoGenomics Laboratories., Myriad Genetics, Inc., GRAIL, LLC., DELFI Diagnostics.

Global Lung Cancer Diagnostic and Screening Market: Key Developments

• In May 2026, Guardant Health, Inc., biotechnology company and Zydus Lifesciences, pharmaceutical company announced the upcoming launch of the Shield multi-cancer detection blood test in India, marking a major step in expanding early cancer screening access. The test is designed to detect multiple cancers from a single blood sample using advanced liquid biopsy technology. The initiative aims to address India’s high burden of late-stage cancer diagnosis and limited screening coverage, improving early detection and clinical outcomes nationwide.
• In September 2025, Mercy BioAnalytics Inc. has raised USD 59 million in Series B financing to advance its extracellular vesicle-based liquid biopsy platform for early cancer detection. The round was co-led by Novalis and Sozo Ventures, with participation from Hologic, Bruker Scientific, Labcorp and others. The funding will support commercialization of Mercy Halo blood-based ovarian cancer tests and expand its portfolio into multi-cancer and lung cancer screening, strengthening early detection capabilities in oncology diagnostics.
• In April 2025, AstraZeneca and Qure.ai announced completion of 5 million AI-enabled chest X-rays across more than 20 countries in Asia, the Middle East, Africa, and Latin America. Using Qure.ai’s qXR technology, the program identified nearly 50,000 people with high-risk lung nodules for further evaluation. The milestone supports scalable, cost-effective lung cancer risk assessment, especially in resource-limited settings where CT capacity and specialist access remain limited in underserved regions.

(Source: Qure.ai)

Market Report Scope

Global Lung Cancer Diagnostic and Screening Market - Key Players

Major players operating in the global lung cancer diagnostic and screening market include Abbott, Amgen Inc., Illumina, Inc., Thermo Fisher Scientific Inc., Lepu Medical Technology (Beijing)Co.,Ltd., AstraZeneca, F. Hoffmann-La Roche Ltd, Laboratory Corporation of America Holdings., Agilent Technologies, Inc., QIAGEN, Quest Diagnostics Incorporated., NeoGenomics Laboratories., Myriad Genetics, Inc., GRAIL, LLC., and DELFI Diagnostics.

Analysts’ Views on Global Lung Cancer Diagnostic and Screening Market

Lung cancer is a disease caused by uncontrolled cell division in the lungs. The rising number of patient population with lung cancer is expected to increase the diagnosis and screening of lung cancer. Thus, it offers the opportunity for various manufacturers to offer innovative lung cancer diagnostic and screening methods that allow for early detection of lung cancer.

Market Segmentation

• By Test Type
  • Biomarkers Test
    • EGFR Mutation Test
    • KRAS Mutation Test
    • ALK Test
    • HER2 Test
    • Others
  • Imaging Test
    • Computed Tomography (CT) scan
    • Positron Emission Tomography (PET) scan
    • Chest X-Ray
    • Others
  • Biopsy 
• By Cancer Type
  • Non-small cell lung cancer
  • Small Cell Lung Cancer Neurosurgery
• By End User 
  • Hospital Associated Labs
  • Independent Diagnostic Laboratories
  • Cancer Research Institutes
  • Others
• By Region
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa

Sources

Primary Research Interviews

• Lung cancer diagnostic/screening vendors (e.g., Roche, Guardant Health, Foundation Medicine, Illumina, GRAIL)
• Pulmonologists, thoracic oncologists and radiologists
• Lung cancer screening program managers

Databases

• U.S. FDA companion diagnostic approvals
• ACR Lung Cancer Screening Registry
• USPSTF lung cancer screening data

Magazines

• OncLive
• CLP Magazine

Journals

• Journal of Thoracic Oncology (IASLC)
• The Lancet Oncology
• Journal of Clinical Oncology (ASCO)

Newspapers

• Reuters Health
• Financial Times – MedTech

Associations

• International Association for the Study of Lung Cancer (IASLC)
• ASCO
• ACR

Public Domain Sources

• USPSTF lung screening recommendations
• NCCN lung cancer guidelines
• ResearchGate publications on lung cancer diagnostics

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of information for last 10 years.

Definition: Lung cancer screening is a process that's used to detect the presence of lung cancer in otherwise healthy people with a high risk of lung cancer. Lung cancer screening is recommended for older adults who are longtime smokers and who don't have any signs or symptoms of lung cancer.